Overview: Investors in ADMA Biologics, Inc. (NASDAQ: ADMA) have incurred significant losses after a sharp stock decline linked to allegations of securities fraud related to revenue reporting.
Background
ADMA Biologics is currently under investigation by multiple law firms for potential violations of federal securities laws. (https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-adma-biologics-inc—adma-302737867.html)
The investigation focuses on whether the company and its executives made false or misleading statements to investors about financial performance.
Summary of Allegations
On March 24, 2026, short-seller Culper Research published a report alleging that ADMA Biologics’ reported financial performance may have been materially misleading. According to the report, the company’s +20% revenue growth in 2025 may have been overstated, with underlying performance potentially closer to negative growth when adjusting for certain sales practices.
The report further alleges that ADMA engaged in “channel stuffing”—a practice in which a company accelerates revenue recognition by pushing excess product into distribution channels, sometimes through incentives such as rebates or extended payment terms. (https://www.globenewswire.com/news-release/2026/04/10/3271626/0/en/ADMA-Securities-Alert-ADMA-Biologics-Securities-Fraud-Investigation-Focuses-on-Channel-Stuffing-Claims-BFA-Law-Notifies-Investors-to-Contact-the-Firm.html)
Stock Price Impact
After the report was released:
- ADMA stock dropped from $13.59 (March 23, 2026)
- To $9.63 (March 25, 2026)
- A dThis represented a decline of approximately 29% over two trading days.https://www.businesswire.com/news/home/20260326859737/en/ADMA-Biologics-Inc.-ADMA-Shareholders-Who-Lost-Money-Contact-Law-Offices-of-Howard-G.-Smith-About-Securities-Fraud-Investigation)
Further declines occurred after analyst downgrades and ongoing scrutiny of the company’s disclosures.
Company Response
ADMA Biologics has publicly denied the allegations, stating:
- Demand for its products remains strong
- Distributor inventory levels are consistent with industry standards
- The claims reflect a misunderstanding of its business model
Why This Matters for Investors
If substantiated, the allegations may support claims that:
- Revenue was artificially inflated
- Financial disclosures were misleading
- Investors relied on inaccurate growth metrics when purchasing shares
Such allegations often form the basis for claims under federal securities laws, including Rule 10b-5.
Investor Guidance
If you purchased ADMA Biologics shares and experienced losses after the March 2026 disclosures, you may have legal options to seek recovery.
Sonn Law Group is currently reviewing potential claims involving:
- Misrepresentation of financial performance
- Unsuitable investment recommendations
- Broker-dealer due diligence failures
Consult an Investor Attorney
Investors affected by losses in ADMA Biologics are encouraged to seek a professional evaluation of their potential claims.
